2 weeks Ago By ABMN Staff
Forefront Analytics LLC raised its stake in shares of Incyte Co. ( NASDAQ:INCY – Free Report ) by 11.3% in the 2nd quarter, according to its most recent disclosure with the SEC.
The firm owned 6,158 shares of the biopharmaceutical company’s stock after purchasing an additional 627 shares during the period. Forefront Analytics LLC’s holdings in Incyte were worth $373,000 as of its most recent SEC filing. Other hedge funds have also bought and sold shares of the company.
MBB Public Markets I LLC bought a new position in shares of Incyte in the second quarter worth about $891,000. APG Asset Management US Inc. boosted its stake in shares of Incyte by 2.
4% in the second quarter. APG Asset Management US Inc. now owns 54,683 shares of the biopharmaceutical company’s stock worth $3,329,000 after acquiring an additional 1,297 shares during the period.
AQR Capital Management LLC boosted its stake in shares of Incyte by 70.5% in the second quarter. AQR Capital Management LLC now owns 2,661,758 shares of the biopharmaceutical company’s stock worth $159,905,000 after acquiring an additional 1,101,041 shares during the period.
AXA S.A. boosted its stake in shares of Incyte by 4.
4% in the second quarter. AXA S.A.
now owns 188,835 shares of the biopharmaceutical company’s stock worth $11,447,000 after acquiring an additional 8,014 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in shares of Incyte by 32.6% in the second quarter.
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 30,129 shares of the biopharmaceutical company’s stock worth $1,826,000 after acquiring an additional 7,403 shares during the period. Institutional investors own 96.97% of the company’s stock.
Insider Transactions at Incyte In other news, EVP Barry P. Flannelly sold 1,306 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $64.
19, for a total value of $83,832.14. Following the sale, the executive vice president now directly owns 58,042 shares in the company, valued at $3,725,715.
98. The sale was disclosed in a document filed with the SEC, which is available at this link . In related news, insider Thomas Tray sold 572 shares of the stock in a transaction that occurred on Thursday, September 12th.
The stock was sold at an average price of $62.94, for a total value of $36,001.68.
Following the transaction, the insider now owns 24,825 shares of the company’s stock, valued at $1,562,485.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website .
Also, EVP Barry P. Flannelly sold 1,306 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $64.
19, for a total value of $83,832.14. Following the completion of the transaction, the executive vice president now directly owns 58,042 shares in the company, valued at approximately $3,725,715.
98. The disclosure for this sale can be found here . Over the last three months, insiders have sold 34,047 shares of company stock worth $2,225,626.
17.50% of the stock is currently owned by company insiders. Wall Street Analyst Weigh In View Our Latest Research Report on INCY Incyte Trading Up 1.
1 % Shares of NASDAQ INCY opened at $65.83 on Friday. The company has a debt-to-equity ratio of 0.
01, a quick ratio of 1.84 and a current ratio of 1.92.
The business’s 50 day moving average price is $64.31 and its 200-day moving average price is $59.96.
Incyte Co. has a fifty-two week low of $50.27 and a fifty-two week high of $70.
36. The company has a market cap of $14.78 billion, a price-to-earnings ratio of 19.
95, a PEG ratio of 5.17 and a beta of 0.73.
Incyte ( NASDAQ:INCY – Get Free Report ) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of $0.
78 by ($2.60). Incyte had a return on equity of 0.
75% and a net margin of 2.52%. The business had revenue of $1.
04 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the company posted $0.
77 earnings per share. The company’s quarterly revenue was up 9.3% compared to the same quarter last year.
On average, sell-side analysts expect that Incyte Co. will post 0.66 earnings per share for the current year.
About Incyte ( Free Report ) Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Further Reading Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Incyte Co. ( NASDAQ:INCY – Free Report ). Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.
com's FREE daily email newsletter ..
